WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 300230

CAS#: 132810-10-7 (free base)

Description: Blonanserin (Lonasen) is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms and excessive sedation and hypotension.

Chemical Structure

CAS# 132810-10-7 (free base)

Theoretical Analysis

MedKoo Cat#: 300230
Name: Blonanserin
CAS#: 132810-10-7 (free base)
Chemical Formula: C23H30FN3
Exact Mass: 367.24238
Molecular Weight: 367.5
Elemental Analysis: C, 75.17; H, 8.23; F, 5.17; N, 11.43

Price and Availability

Size Price Availability Quantity
25.0mg USD 210.0 2 weeks
Bulk inquiry

Related CAS #: 132812-45-4 (HCl)   132810-10-7 (free base)   132812-47-6 (citrate)    

Synonym: 2(4ethylpiperazin1yl)4(4fluorophenyl)5678910hexahydrocyclooctabpyridine

IUPAC/Chemical Name: 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine.


InChi Code: InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO (10 mg/mmL)

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 367.5 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Hamuro A, Saito S. Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin. Psychogeriatrics. 2010 Dec;10(4):198-200. doi: 10.1111/j.1479-8301.2010.00338.x. PubMed PMID: 21159055.

2: Ohoyama K, Yamamura S, Hamaguchi T, Nakagawa M, Motomura E, Shiroyama T, Tanii H, Okada M. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol. 2010 Dec 11. [Epub ahead of print] PubMed PMID: 21147094.

3: Ogawa T, Hattori H, Kaneko R, Ito K, Iwai M, Mizutani Y, Arinobu T, Ishii A, Suzuki O, Seno H. Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Sci. 2010;26(10):1099-102. PubMed PMID: 20953055.

4: Andoh H, Kato K, Sato R, Akama F, Sakaguchi T, Matsumoto H. Case of delirium complicated with pneumonia that improved with blonanserin administration. Psychiatry Clin Neurosci. 2010 Oct;64(5):588-9. doi: 10.1111/j.1440-1819.2010.02124.x. PubMed PMID: 20923437.

5: Yang J, Bahk WM, Cho HS, Jeon YW, Jon DI, Jung HY, Kim CH, Kim HC, Kim YK, Kim YH, Kwon JS, Lee SY, Lee SH, Yi JS, Yoon BH, Kim SH. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010 Jul;33(4):169-75. PubMed PMID: 20661022.

6: Ishitobi M, Kosaka H, Shukunami K, Murata T, Wada Y. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1361-2. Epub 2010 Jul 18. PubMed PMID: 20647025.

7: Suzuki H, Gen K. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity. Hum Psychopharmacol. 2010 Jun;25(4):342-6. PubMed PMID: 20521325.

8: Saruwatari J, Yasui-Furukori N, Inoue Y, Kaneko S. Effect of dose timing in relation to food intake on systemic exposure to blonanserin. Eur J Clin Pharmacol. 2010 Sep;66(9):899-902. Epub 2010 May 20. PubMed PMID: 20490472.

9: Ohno Y, Okano M, Imaki J, Tatara A, Okumura T, Shimizu S. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. Pharmacol Biochem Behav. 2010 Aug;96(2):175-80. Epub 2010 May 10. PubMed PMID: 20460137.

10: Furuse T, Hashimoto K. Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. Ann Gen Psychiatry. 2010 Apr 24;9:17. PubMed PMID: 20416096; PubMed Central PMCID: PMC2868038.